Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420

What Was Tested

This randomized controlled trial paper looks at Pancreatic Polypeptide and Neuropeptide Y.

Who Took Part

According to the abstract, 1420 subjects were involved.

The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The subjects were allocated by chance, so the Pancreatic Polypeptide group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Pancreatic Polypeptide.

A placebo (an inactive look-alike) gave the Pancreatic Polypeptide group a baseline to be compared against.

This was a double-blind, placebo-controlled, randomized study.

Standard safety and laboratory data were collected.

The primary endpoint was the tolerability of PP 1420.

The secondary endpoint was exposure to PP 1420 as assessed by C(max) and AUC(0,∞).

What Was Measured

The subject headings attached to it are Appetite, Appetite Depressants, Area Under Curve, Obesity, Pancreatic Polypeptide, Receptors, Neuropeptide Y and United Kingdom.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Pancreatic Polypeptide and Neuropeptide Y in 1420 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (British journal of clinical pharmacology), a journal based in England.

More context: the Pancreatic Polypeptide compound page and the Neuropeptide Y compound page.